The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis

Jeffery J. Auletta, Amelia M. Bartholomew, Richard T. Maziarz, Robert J. Deans, Robert H. Miller, Hillard M. Lazarus, Jeffrey A. Cohen

Research output: Contribution to journalReview articlepeer-review

48 Scopus citations


Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the CNS for which only partially effective therapies exist. Intense research defining the underlying immune pathophysiology is advancing both the understanding of MS as well as revealing potential targets for disease intervention. Mesenchymal stromal cell (MSC) therapy has the potential to modulate aberrant immune responses causing demyelination and axonal injury associated with MS, as well as to repair and restore damaged CNS tissue and cells. This article reviews the pathophysiology underlying MS, as well as providing a cutting-edge perspective into the field of MSC therapy based upon the experience of authors intrinsically involved in MS and MSC basic and translational science research.

Original languageEnglish (US)
Pages (from-to)529-547
Number of pages19
Issue number5
StatePublished - May 2012


  • IFN-γ
  • Th17 cell
  • Toll-like receptor
  • experimental autoimmune encephalomyelitis
  • immunomodulation
  • inflammation
  • mesenchymal stromal cell
  • multiple sclerosis
  • transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis'. Together they form a unique fingerprint.

Cite this